Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Cancer Conference Journal

30-03-2024 | Myocarditis | Case report - Complication

An autopsy case of lung adenocarcinoma with immune checkpoint inhibitor-induced pneumonia and fulminant myocarditis following pembrolizumab administration: a case report

Authors: Takahiko Hashimoto, Kosuke Takahashi, Kosuke Ito, Kahori Iwade, Atsushi Torii, Minoru Sugihara, Haruka Kondo, Toru Hara

Published in: International Cancer Conference Journal

Login to get access

Abstract

Immune checkpoint inhibitors (ICIs) are the current standard of care for non-small-cell lung cancer (NSCLC). Myocarditis is a rare but serious immune-related adverse event (irAE) associated with ICI therapy. We present a patient who received a single dose of pembrolizumab for NSCLC and developed ICI-associated pneumonia. Although pneumonia improved with corticosteroid therapy, the patient subsequently developed ICI-associated fulminant myocarditis. Despite high-dose corticosteroid therapy, the patient died on day 30 after pembrolizumab initiation. Even if an observed irAE was effectively treated, clinicians should remain vigilant for other irAEs, especially those that are difficult to control with low-dose corticosteroids.
Literature
1.
2.
Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639CrossRefPubMedPubMedCentral
3.
Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1- positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550CrossRefPubMed
4.
Felip E, Altorki N, Zhou C et al (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398:1344–1357CrossRefPubMed
5.
6.
Wang DY, Salem JE, Cohen JV et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4:1721–1728CrossRefPubMedPubMedCentral
7.
8.
Salem JE, Manouchehri A, Moey M et al (2018) Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579–1589CrossRefPubMedPubMedCentral
9.
Kindermann I, Barth C, Mahfoud F et al (2012) Update on myocarditis. J Am Coll Cardiol 59:779–792CrossRefPubMed
10.
11.
Shannon VR, Anderson R, Blidner A et al (2020) Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Support Care Cancer 28:6145–6157CrossRefPubMedPubMedCentral
12.
Lyon AR, Yousaf N, Battisti NML et al (2018) Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19:e447–e458CrossRefPubMed
13.
Palaskas N, Lopez-Mattei J, Durand JB et al (2020) Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc 9:e013757CrossRefPubMedPubMedCentral
14.
Arangalage D, Delyon J, Lermuzeaux M et al (2017) Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann Intern Med 167:683–684CrossRefPubMed
15.
Esfahani K, Buhlaiga N, Thébault P et al (2019) Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N Engl J Med 380:2375–2376CrossRefPubMed
16.
Salem JE, Allenbach Y, Vozy A et al (2019) Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med 380:2377–2379CrossRefPubMed
17.
Pathak R, Katel A, Massarelli E et al (2021) Immune checkpoint inhibitor-induced myocarditis with myositis/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist 26:1052–1061CrossRefPubMedPubMedCentral
Metadata
Title
An autopsy case of lung adenocarcinoma with immune checkpoint inhibitor-induced pneumonia and fulminant myocarditis following pembrolizumab administration: a case report
Authors
Takahiko Hashimoto
Kosuke Takahashi
Kosuke Ito
Kahori Iwade
Atsushi Torii
Minoru Sugihara
Haruka Kondo
Toru Hara
Publication date
30-03-2024
Publisher
Springer Nature Singapore
Published in
International Cancer Conference Journal
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-024-00665-7
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits